^89SrCl2在治疗乳腺癌骨转移中的临床疗效

Clinical effect of ^89SrCl2 in the treatment of breast cancer patients with bone metastasis

目的评价^89SrCl2治疗乳腺癌骨转移的临床疗效，及其血液学毒副作用。方法51例患者接受^89SrCl2治疗，静脉注射剂量为2．22MBq／kg体重，观察治疗前后止痛效果，病灶变化和外周血细胞变化。结果患者疼痛完全缓解率为37．7％（17／45），总缓解率为84．4％。病灶治疗有效率为62．7％（32／51）。治疗后1个月白细胞和血小板减少者分别为76．5％和62．7％。3个月后大多数患者经治疗血象恢复到正常。结论^89SrCl2可安全、有效地治疗乳腺癌骨转移患者的疼痛，并对其生活质量有所改善。

Objective To evaluate the clinical effect of ^89SrCl2 as a palliative therapy for breast cancer patients with bone metastasis, and to observe the hematological toxicity induced by ^89SrCl2 treatment. Methods ^89SrCl2 dosage was 2.22 MBq/kg each time by intravenous for 51 patients. The analog scale, the cancer size and the hematological toxicity of ^89SrCl2 treatment were observed. Results 17 patients （37.7 % ） among 45 patients became free of pain. The total pain relief rate was 84.4% .The response rate of metastatic sites was 62.7%. Approximately 76.5 % of patients experienced neutropenia one month after theatment, whereas 62.7 % of patients experienced thrombocytopenia. But the most of the patients could recover to the normal level 3 months after treatment. Condusions ^89SrCl2 is an effective and safe way for the pain relief and the life quality improvement in breast cancer patients with bone metastasis.